Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

IO102-IO103 / IO Biotech

2021-003026-69: A study investigating the use of IO102-IO103 in combination with pembrolizumab for patients with metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or metastatic Urothelial Bladder Cancer (mUBC)

Not yet recruiting

Europe

IO102-IO103 + Montanide ISA 51 VG Sterile, Emulsion for injection

IO Biotech ApS, IO Biotech ApS

Metastatic Non-Small Cell Lung Cancer (NSCLC), Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC) cáncer de pulmón no microcítico (CPNM) metastásico, carcinoma de células escamosas de cabeza y cuello (CCECC) metastásico, carcinoma urotelial de vejiga metastásico (CUVm), Lung Cancer, Head and Neck Cancer, Bladder Cancer Cáncer de pulmón, cáncer de cabeza y cuello, cáncer de vejiga, Diseases [C] - Cancer [C04]

KEYNOTE-D38, NCT05077709: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Recruiting

Europe, US

IO102-IO103 in combination with pembrolizumab

IO Biotech, Theradex, Almac, NeoGenomics, Merck Sharp & Dohme LLC

Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder

04/24

11/24

KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Recruiting

Europe, US, RoW

IO102-IO103, Pembrolizumab KEYTRUDA®

IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC

Melanoma, Squamous Cell Carcinoma of Head and Neck

04/25

01/27

NCT05912244: A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Recruiting

IO102/IO103, Nivolumab-Relatlimab

Memorial Sloan Kettering Cancer Center, IO Biotech

Melanoma

06/27



	Diseases Companies Products Productz Mechanisms of Action Sites